About Santhera
Santhera is a company based in Liestal (Switzerland) founded in 2004 by Thomas Meier. The company has 78 employees. Santhera has completed 1 acquisition, including Oy Juvantia Pharma. Santhera offers products and services including AGAMREE® (vamorolone). Santhera operates in a competitive market with competitors including Jazz Pharmaceuticals, Lundbeck, Kriya Therapeutics, Sana Biotechnology and PureTech Health, among others.
- Headquarter Liestal, Switzerland
- Employees 78
- Founders Thomas Meier
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Website santhera.com
- Social LinkedIn X
- Legal Name Santhera Pharmaceuticals Holding Ag
- Annual Revenue$97.38 M (USD)97.32as on Dec 31, 2025
- Net Profit-$62.12 M (USD)-17.3as on Dec 31, 2025
- EBITDA-$40.53 M (USD)-15.84as on Dec 31, 2025
- InvestorsIdorsia
& 5 more
- Employee Count78
- Investments & Acquisitions
Products & Services of Santhera
Santhera offers a comprehensive portfolio of products and services, including AGAMREE® (vamorolone).
Treatment for Duchenne muscular dystrophy to address unmet needs.
Funding Insights of Santhera
- Total Rounds 10
- Investors Count 6
All 10 funding rounds of Santhera with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2023 | – | Post-IPO | – | – | |
| Sep 2021 | $1.2M | Grant | – | – | |
| Sep 2021 | $48.26M | Post-IPO | – | – | |
| Apr 2021 | $64.15M | Post-IPO | – | – | – |
| Nov 2020 | – | Post-IPO | – | – | |
| Apr 2020 | – | Post-IPO | – | – | |
| May 2019 | $14.72M | Debt – Conventional | – | – | – |
| Apr 2019 | $7.12M | Post-IPO | – | – | – |
| Dec 2018 | $23.66M | Post-IPO | – | – | – |
| Jun 2008 | – | Post-IPO | – | – |
6 investors in total: 6 institutional.
Investors in Santhera
Santhera has secured backing from 6 investors, including institutional and venture fund investors. Prominent investors backing the company include Idorsia, IRIS and Highbridge.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
B-FLEXION is engaged in private entrepreneurial investment activities. | – | bflexion.com | - | |
- | – | highbridge.com | - | |
The U.S. Food and Drug Administration is tasked with regulating food, drugs, and medical products. | – | fda.gov | United States | |
Diversified drugs are developed and manufactured for multiple therapeutic areas. | 2017 | idorsia.com | Allschwil, Switzerland | |
Multiple educational programs are provided by IRIS as an NGO. | 1991 | iris-france.org | Paris, France | |
B-FLEXION is recognized as a private entrepreneurial investment firm. | – | waypointcapital.net | - |
Investor details for Santhera
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Santhera
33 people are tracked at Santhera (19 in leadership, 3 in board & advisors, 11 in team); the tracked headcount is 78.
| Name | Role | Group |
|---|---|---|
Thomas Meier | Founder & CEO | Leadership |
Sarah Holmes-Klotz | Head, People & Culture | Leadership |
Marc Schrader | Chief Technology Officer | Leadership |
Jeff Koester | Head, US Medical Affairs At Santhera Pharmaceuticals | Leadership |
Stéphane Wilzius | Head Of Clinical Operations | Leadership |
Dario Eklund | Chief Executive Officer | Leadership |
Günther Metz | Head, Business Development & EVP | Leadership |
Andreas Missy | Chief of Staff | Leadership |
Shabir Hasham | Chief Medical Officer | Leadership |
Chuck Sininski | Vice President Finance | Leadership |
Nathalie Zeiri | CEO Assistant / Board Management Support | Leadership |
Tomas Chleborad | People & Culture Business Partner, Europe | Leadership |
Ivana Caramazza | People & Culture Business Partner | Leadership |
Sylvia Stephan | People & Culture Talent Acquisition Partner | Leadership |
Omer de Mol | Global Head Drug Safety And Pharmacovigilance | Leadership |
Dr. Wido Tilmann | Medical Director DACH | Leadership |
Rosana Muñoz Hervás | General Manager Iberia (spain & Portugal) | Leadership |
Jane Barry | Medical Director UK & Ireland | Leadership |
Elodie Denjean | General Manager Uk, France & Benelux | Leadership |
Otto Schwarz | Board Member | Board & advisors |
13 more people are available in the full profile.
Complete people profiles for Santhera
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Santhera
Santhera is a publicly listed company on the SIX with ticker symbol SANN in Switzerland, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date03 Nov 2006
- Listed onSWX: SANN
- Listed entitySanthera Pharmaceuticals Holding AG
- Exchange sectorHealth technology
- ISINCH1276028821
- Share price17.04 CHF (-0.47% on the day) · 2026-05-11
- Market capitalisation248,300,977.00 CHF
- EPS (diluted, trailing year)-3.82 CHF
- Volume (last session)24,660
- Analyst consensusStrong buy
Financials of Santhera
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 77.2M CHF | -49.2M CHF | -32.1M CHF |
| 2024 | 39.1M CHF | -42.0M CHF | -27.7M CHF |
| 2023 | 103.4M CHF | 54.8M CHF | 53.6M CHF |
| 2022 | 7.5M CHF | -71.1M CHF | -42.2M CHF |
| 2021 | -1.6M CHF | -55.5M CHF | -53.4M CHF |
Detailed financial statements for Santhera
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Santhera
Santhera has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Oy Juvantia Pharma.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Small molecules are developed for Dyskinesia in Parkinson’s Disease treatment. | juvantia.com | Turku, Finland | 1997 | Aug 2009 | $4M |
Complete acquisition details for Santhera
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Santhera
5 dated milestones of Santhera across 19 years, from founding to its latest funding, stage changes and deals.
- Founded Santhera is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round.
- Acquisition Acquires Oy Juvantia Pharma.
- Funding Latest funding round, Post-IPO,.
Competitors of Santhera
Santhera operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Lundbeck, Kriya Therapeutics, Sana Biotechnology and PureTech Health, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| jazzpharma.com | 2003 | Dublin, Ireland | $265M | 2,800 | Novel biopharmaceutical medicines are developed for unmet medical needs. | |
| lundbeck.com | 1915 | Copenhagen, Denmark | – | 393 | Drugs for CNS disorders are developed and advanced. | |
| kriyatherapeutics.com | 2012 | Redwood, United States | $930.93M | 159 | Developer of therapeutic solutions for the treatment of diabetes | |
| sana.com | 2018 | Seattle, United States | $821M | 328 | Genetically engineered cell therapies are developed for multiple disorders. | |
| puretechhealth.com | 2001 | Boston, United States | $107M | 171 | Immunotherapeutics are developed for inflammation, fibrosis, and lung diseases. | |
| ultragenyx.com | 2010 | Novato, United States | $135.1M | 837 | Therapeutics for rare and ultra-rare metabolic diseases are developed. | |
| biohavenpharma.com | 2014 | New Haven, United States | $84.1M | 932 | Therapies for neurological and neuropsychiatric diseases are developed. | |
| karunatx.com | 2009 | Boston, United States | $132.1M | 339 | Therapies for psychosis and cognitive impairment are developed. | |
| alnylam.com | 2002 | Cambridge, United States | $17M | 2,100 | RNA interference-based therapeutics are developed for multiple disorders. |
Detailed competitors of Santhera
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Santhera
The website of Santhera (santhera.com) receives about 12.6K visits a month and ranks #3,177,070 among all websites worldwide, #4,183 in Biotechnology and Pharmaceuticals.
- Monthly visits12.6K
▲ 86% vs previous month
- Unique visitors2.9K
per month
- Global rank#3,177,070
among all websites
- Category rank#4,183
Health · Biotechnology and Pharmaceuticals
- Bounce rate48%
- Pages per visit1.5
- Average visit12 sec
- DevicesDesktop 32% · Mobile 68%
Websites whose visitors overlap most with Santhera. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| actelion.com | 100% | – | – | View details | |
| newron.com | 99% | 8.8K | #2,677,447 | View details | |
| basilea.com | 91% | 7.8K | #2,173,854 | View details | |
| eisai.com | 84% | 74.5K | #534,857 | View details | |
| ptcbio.com | 83% | 24.4K | #1,154,739 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 22 similar websites and full traffic analytics for Santhera
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 22 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Latest news on Santhera
Complete news archive for Santhera
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Santhera
10 companies that operate in the same segment as Santhera (Rare Diseases), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Solutions for genetic diseases are developed using CRISPR-Cas9 genome editing. | 2013 | Basel, Basel-stadt, Switzerland | USD 127 M | USD 37.31 M | 393 | |
Gene therapies for rare diseases are developed to treat patients. | 2020 | Columbus, Ohio, United States | USD 250 M | – | – | |
Developing small molecules for control mechanisms and genes regulation for the treatment of rare diseases | 2015 | Cambridge, Massachusetts, United States | USD 114.67 M | – | 45 | |
Developer of peptide therapeutics for the treatment of rare genetic deficiencies | 2010 | Boston, Massachusetts, United States | USD 84 M | USD 189.76 M | 283 | |
RNA interference-based therapeutics are developed for multiple disorders. | 2002 | Cambridge, Massachusetts, United States | USD 17 M | USD 3.71 B | 2,230 | |
Biologics platform developed for intracellular delivery in rare diseases. | 2016 | Boston, Massachusetts, United States | USD 175.25 M | USD 25.42 M | 183 | |
Therapies for gastrointestinal diseases are developed by Phathom Pharmaceuticals. | 2019 | Menlo Park, California, United States | USD 90 M | USD 175.11 M | 427 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Santhera
Santhera was founded in 2004 and raised its 1st funding round 4 years after it was founded.
Santhera is headquartered in Liestal, Switzerland. It is registered at Liestal, Basel-landschaft, Switzerland.
Thomas Meier is the current CEO of Santhera. They have also founded this company.
Santhera has 78 employees.
Annual revenue of Santhera is $97.38M as on Dec 31, 2025.
Santhera was founded in 2004 and is headquartered in Liestal, Switzerland. Focus is placed on the development of pharmaceutical treatments targeting mitochondrial and neuromuscular diseases. Operations center on innovative drug candidates, including Vamorolone, a dissociative steroid designed for Duchenne muscular dystrophy. The company operates within the biotechnology sector, with activities spanning research, clinical trials, and regulatory processes across Europe.
Santhera's top competitors include Jazz Pharmaceuticals, Alnylam and Biohaven Pharmaceutical.
Santhera offers AGAMREE® (vamorolone).
Yes, Santhera is publicly traded on SIX under the ticker symbol SANN.
Santhera has made 1 acquisition, including Oy Juvantia Pharma.
Santhera has 6 investors. Key investors include Idorsia, IRIS, Highbridge, U.S. Food and Drug Administration, and B-FLEXION.
Santhera operates through Santhera Pharmaceuticals.